Alpha-GPC
Also known as: Alpha-glycerophosphocholine, L-Alpha glycerylphosphorylcholine, Choline alfoscerate
This ingredient is classified as unclassified risk (GIRI score: 2.5/10).
Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Alpha-GPC is a highly bioavailable choline precursor that crosses the blood-brain barrier and supports acetylcholine synthesis. It is well tolerated at doses up to 1200 mg/day. Headache, GI upset, and insomnia have been reported at high doses. A large epidemiological study raised a concern about increased cardiovascular event risk with long-term high-dose choline supplementation, though causality for Alpha-GPC specifically is not established. Mild drug interactions with anticholinergic medications are possible.
Biological and Chemical Classification
Information not yet available for this ingredient profile.
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Nootropics
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Alpha-GPC indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 26 მარ 2026, 14:04
Evidence Distribution
-
Observational / other LOW evidence YELLOWLimosilactobacillus mucosae attenuates hyperlipidemic periodontitis via the gut-oral axis. ↗Xu J et al.. Limosilactobacillus mucosae attenuates hyperlipidemic periodontitis via the gut-oral axis.. Gut Microbes. 2026. PMID:41556761.PMID 41556761 ↗Journal Gut MicrobesYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41556761/
-
Observational / other LOW evidence YELLOWCase Report: A case of post-viral inflammatory insomnia: observed sleep restoration associated with histamine-targeted interventions and implications for mast cell pathways. ↗Meckes AJ et al.. Case Report: A case of post-viral inflammatory insomnia: observed sleep restoration associated with histamine-targeted interventions and implications for mast cell pathways.. Front Sleep. 2025. PMID:41640426.PMID 41640426 ↗Journal Front SleepYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41640426/
-
Observational / other LOW evidence YELLOWL-Alpha-Glycerylphosphorylcholine (L-u03b1-GPC): A Comprehensive Review of Its Preparation Techniques and Versatile Biological Effects. ↗Li J et al.. L-Alpha-Glycerylphosphorylcholine (L-u03b1-GPC): A Comprehensive Review of Its Preparation Techniques and Versatile Biological Effects.. J Food Sci. 2025. PMID:40556032.PMID 40556032 ↗Journal J Food SciYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40556032/
-
Observational / other LOW evidence YELLOWCholine Alphoscerate: A Therapeutic Option for the Management of Subthreshold Depression in the Older Population. ↗Granata N et al.. Choline Alphoscerate: A Therapeutic Option for the Management of Subthreshold Depression in the Older Population.. Geriatrics (Basel). 2025. PMID:40126282.PMID 40126282 ↗Journal Geriatrics (Basel)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40126282/
-
Observational / other LOW evidence YELLOWUnlocking the potential of l-u03b1-glycerylphosphorylcholine in the food industry: From safety approvals to market prospects. ↗Cao J et al.. Unlocking the potential of l-u03b1-glycerylphosphorylcholine in the food industry: From safety approvals to market prospects.. Compr Rev Food Sci Food Saf. 2025. PMID:39898924.PMID 39898924 ↗Journal Compr Rev Food Sci Food SafYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39898924/
-
Observational / other LOW evidence YELLOWTreatment with soybean lecithin-derived u03b1-GPC (SHCogu2122) improves scopolamine-induced cognitive declines in mice via regulating cholinergic neurotransmission and enhancing neural plasticity in the… ↗Zheng Y et al.. Treatment with soybean lecithin-derived u03b1-GPC (SHCogu2122) improves scopolamine-induced cognitive declines in mice via regulating cholinergic neurotransmission and enhancing neural plasticity in the hippocampus.. Tissue Cell. 2025. PMID:39765138.PMID 39765138 ↗Journal Tissue CellYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39765138/
-
Observational / other LOW evidence YELLOWSafety evaluation of alpha-glycerylphosphorylcholine as a novel food. ↗Tian J et al.. Safety evaluation of alpha-glycerylphosphorylcholine as a novel food.. Food Chem Toxicol. 2025. PMID:39577616.PMID 39577616 ↗Journal Food Chem ToxicolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39577616/
-
Observational / other LOW evidence YELLOWProduction of u03b1-Glycerylphosphorylcholine in Fermented Roots, Tubers, and Fruits. ↗Tse TJ et al.. Production of u03b1-Glycerylphosphorylcholine in Fermented Roots, Tubers, and Fruits.. Foods. 2024. PMID:39410120.PMID 39410120 ↗Journal FoodsYear 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39410120/
-
Observational / other LOW evidence YELLOWPharmacological enhancement of cholinergic neurotransmission alleviates neuroinflammation and improves functional outcomes in a triple transgenic mouse model of Alzheimer's disease. ↗Munafu00f2 A et al.. Pharmacological enhancement of cholinergic neurotransmission alleviates neuroinflammation and improves functional outcomes in a triple transgenic mouse model of Alzheimer's disease.. Front Pharmacol. 2024. PMID:38595916.PMID 38595916 ↗Journal Front PharmacolYear 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/38595916/
-
Observational / other LOW evidence YELLOWTaming Microglia in Alzheimer's Disease: Exploring Potential Implications of Choline Alphoscerate via u03b17 nAChR Modulation. ↗Cantone AF et al.. Taming Microglia in Alzheimer's Disease: Exploring Potential Implications of Choline Alphoscerate via u03b17 nAChR Modulation.. Cells. 2024. PMID:38391922.PMID 38391922 ↗Journal CellsYear 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/38391922/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Alpha-GPC. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Alpha-GPC
A score of 2.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.